Table 2.
Selected ongoing trials of combination strategies with PARP inhibition.
| Drug | PARP Inhibitor | Phase | Tumor Type | NCT |
|---|---|---|---|---|
| Cytotoxic | ||||
| Platinums | ||||
| Carboplatin | Olaparib | I | Solid tumors | 02418624 |
| Carboplatin + paclitaxel | Talazoparib | I | Solid tumors | 02317874 |
| Carboplatin + paclitaxel | Veliparib | III | Breast | 02163694 |
| Carboplatin + etoposide | Veliparib | II | SCLC | 02289690 |
| Carboplatin + gemcitabine | Veliparib | II | Germ cell | 02860819 |
| Carboplatin + paclitaxel + avastin | Olaparib | III | Ovarian | 02477644 |
| Cisplatin | Veliparib | II | Breast | 02595905 |
| Cisplatin + gemcitabine | Talazoparib | I | Solid tumors | 02537561 |
| Temozolomide-based | ||||
| Irinotecan +/− temozolomide | Talazoparib | I | Paediatric tumors | 02392793 |
| Temozolomide or irinotecan | Niraparib | I | Ewing’s sarcoma | 02044120 |
| Temozolomide + capecitabine | Veliparib | I | PNET | 02831179 |
| 5FU-based | ||||
| FOLFOX | Veliparib | I/II | Pancreas | 0149865 |
| FOLFIRI | Veliparib | II | Pancreas | 02890355 |
| Others | ||||
| Liposomal irinotecan | Veliparib | I | Solid tumors | 02631733 |
| Decitabine | Talazoparib | I | AML | 02878785 |
| Radiation | ||||
| RT | Olaparib | I | HNSCC | 02229656 |
| RT | Olaparib | I | Breast | 02227082 |
| RT | Olaparib | I | Esophagus | 01460888 |
| RT | Olaparib | I | Sarcoma | 02787642 |
| RT +/− cisplatin | Olaparib | I | NSCLC | 01562210 |
| RT + carboplatin + paclitaxel | Veliparib | I/II | NSCLC | 01386385 |
| Rd223 | Niraparib | I | Prostate | 03076203 |
| Targeted therapy | ||||
| Cell cycle check point inhibitors | ||||
| AZD1775 (Wee1) | Olaparib | I | Solid tumors | 02511795 |
| Prexasertib (CHK1) | Olaparib | I | Solid tumors | 03057145 |
| VX-970 (ATR) + cisplatin | Veliparib | I | Solid tumors | 02723864 |
| Dinaciclib (CDK) | Veliparib | I | Solid tumors | 01434316 |
| Anti-angiogenics | ||||
| Cediranib (VEGF) | Olaparib | II | Ovarian; GBM; solid tumors; | 02345265; 02974621; 02498613 |
| Ramucirumab (VEGF) | Olaparib | I/II | Gastric | 03008278 |
| Bevacizumab (VEGF) | Niraparib | I/II | Ovarian | 02354131 |
| PI3K/AKT/mTOR pathway | ||||
| AZD5363 (PI3K) | Olaparib | I | Solid tumors | 02338622 |
| Everolimus (mTOR) | Niraparib | I | Breast, ovarian | 03154281 |
| Other targeted therapies | ||||
| Selumetinib | Olaparib | I | Solid tumors | 03162627 |
| AT13387 (Hsp90) | Olaparib | I | Ovarian and breast | 02898207 |
| Lapatanib (HER2) | Veliparib | I | Breast | 02158507 |
| Hormonal therapy | ||||
| Abiraterone | Olaparib | II | Prostate | 01972217 |
| Enzalutamide | Niraparib | I | Prostate | 02500901 |
| Immunotherapy | ||||
| Anti-PD1 | ||||
| Nivolumab | Veliparib | I | Solid tumors, lymphoma | 03061188 |
| Pembrolizumab | Niraparib | I | Breast, ovarian | 02657889 |
| Nivolumab + platinum doublet | Veliparib | II | NSCLC | 02944396 |
| Anti-PDL1 | ||||
| Durvalumab | Olaparib | II | Breast | 03167619 |
| Durvalumab + tremelimumab | Olaparib | I | Ovarian | 02953457 |
| Atezolizumab | Rucaparib | I | Gynaecological | 03101280 |
| Atezolizumab | Veliparib | II | Breast | 02849496 |